Search Results
Your search for ,aLl matches 18304 pages
Showing 6201 - 6250Panel With Diverse Perspectives Explores Strategies to Reduce Costs for Cancer Care
“Imagine that it’s 5 years from now, and we are in a situation where the cost of cancer care has flattened, and costs are even going down,” said Clifford Goodman, PhD, a Senior Vice President at the Lewin Group, turning to a panel of oncology and policy experts at his side. “What policies got us...
Daughter of an Orthopedic Surgeon, Abigail T. Berman, MD, Finds Radiation Oncology Intriguing
Radiation oncologist Abigail T. Berman, MD, was born and reared in Philadelphia, the daughter of an orthopedic surgeon whose passion for his work was an early influence on her decision to pursue a career in medicine. “My father absolutely adored his job and worked very hard, which inspired me to...
ASTRO Calls for Changes to Benefits Manager Policy That Disrupts Patient/Physician Decision-Making for Cancer Radiotherapy
Radiation oncologists have expressed serious concerns about a new private insurance coverage policy that could undermine patient-centered care for two of the most common cancers in the United States. Leaders of the American Society for Radiation Oncology (ASTRO) urge eviCore, a radiation oncology...
Dana-Farber Announces Center for Salivary and Rare Head and Neck Cancers
Dana-Farber Cancer Institute has launched the Center for Salivary and Rare Head and Neck Cancers to treat patients with rare and occasionally aggressive cancers arising from the head and neck. The Center is among the first in the country specifically dedicated to the care and therapeutic research...
Cancer in Older Adults: The History of Geriatric Oncology, Part 2: 1990–2020
In part 1 of this three-part article, which was published in the October 10, 2020, issue of The ASCO Post, we chronicled the progress made in geriatric oncology up to the decade of the 1990s, which saw an explosion of research activity in the study of aging and cancer. In part 2, we review the...
James K. McCloskey II, MD, Named Division Chief of the Division of Leukemia at John Theurer Cancer Center
James K. McCloskey II, MD, was named Division Chief of the Division of Leukemia at Hackensack Meridian John Theurer Cancer Center (JTCC), part of Hackensack University Medical Center. Dr. McCloskey previously served as Interim Chief for the Division of Leukemia and will continue in his role as...
First-Line Pembrolizumab in Metastatic Colorectal Cancer: Quality of Life Also Improved
In KEYNOTE-177, the anti–PD-L1 antibody pembrolizumab reduced the risk of disease progression by 40% vs chemotherapy in a targeted subset of previously untreated patients with metastatic colorectal cancer. Now, in terms of health-related quality of life, pembrolizumab is also the clear favorite,...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
Activity of the KRAS G12C Inhibitor Sotorasib in KRAS G12C–Mutant Advanced Solid Tumors
As reported inThe New England Journal of Medicine by David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues, a phase I trial (CodeBreak 100) has shown activity of the oral KRAS G12C inhibitor sotorasib in heavily pretreated patients with KRAS G12C–mutant...
Capmatinib Active in Advanced NSCLC With MET Exon 14 Skipping Mutations
As reported inThe New England Journal of Medicine by Jürgen Wolf, MD, of the Center for Integrated Oncology, University Hospital Cologne and University of Cologne, and colleagues, the phase II GEOMETRY mono-1 trial has shown durable responses with the selective MET inhibitor capmatinib in patients...
Anthony Fauci, MD, to Receive Lifetime Achievement Award From National Minority Quality Forum
The National Minority Quality Forum announced that Anthony Fauci, MD, will receive its 2020 Bernard J. Tyson Lifetime Achievement Award, which recognizes health-care leaders who have helped to decrease health disparities and to build sustainable healthy communities. Dr. Fauci—who has served as...
Thinking Out of the Box to Advance the Management of Chronic Graft-vs-Host Disease
Over the past decade, the field of allogeneic hematopoietic cell transplantation has made great strides, evolving into a curative procedure for blood cancers that once were almost always fatal. However, chronic graft-vs-host disease, whose biologic etiology remains unclear, continues to be the...
Ipatasertib/Abiraterone Combination Shows Potential in Metastatic Castration-Resistant Prostate Cancer With PTEN Loss
Ipatasertib plus abiraterone plus prednisone achieved significantly superior radiographic progression–free survival and antitumor activity compared with placebo plus abiraterone plus prednisonein patients with metastatic castration-resistant prostate cancer and PTEN loss, according to the results...
Olaparib Improves Outcomes in Metastatic Castration-Resistant Prostate Cancer With BRCA1/2 Alterations
The PARP inhibitor olaparib reduced the risk of death by 31% compared with a second hormonal treatment (enzalutamide or abiraterone) in men with metastatic castration-resistant prostate cancer characterized by BRCA1, BRCA2, or ATM mutations, in the final analysis of the phase III PROfound trial...
Emmanuelle Charpentier, PhD, and Jennifer A. Doudna, PhD, Honored With Nobel Prize in Chemistry 2020
On October 7, 2020, The Royal Swedish Academy of Sciences announced that the Nobel Prize in Chemistry 2020 would be awarded to Emmanuelle Charpentier, PhD, and Jennifer A. Doudna, PhD, “for the development of a method for genome editing,” the CRISPR/Cas9 genetic scissors. “There is enormous power...
2020 Nobel Prize in Physiology or Medicine Awarded to Team Who Discovered Hepatitis C Virus
This year’s Nobel Prize in Physiology or Medicine was awarded to three scientists who have made a decisive contribution to the treatment of blood-borne hepatitis, a major global health problem that causes cirrhosis and liver cancer in people around the world. Harvey J. Alter, MD; Michael Houghton,...
Early-Phase Study Reports Progress in Targeting KRAS-Mutated Tumors With Sotorasib
Although KRAS is one of the most frequently mutated oncogenes in human cancers, an almost 4-decade long search for drugs that hit this target has been elusive—until now. Sotorasib (formerly called AMG-510), a small-molecule inhibitor of the KRAS G12C mutation, demonstrated clinical activity and...
Co-Leader of Immunotherapy Trial Reflects on ‘Practice-Changing’ Results in Advanced Bladder and Other Urinary Tract Cancers
In a large, randomized clinical trial, researchers evaluated the immunotherapy drug avelumab for patients with advanced urothelial cancer. The findings of the trial, called the JAVELIN Bladder 100 study, are “very exciting,” even “practice-changing,” said the trial’s co-leader, Petros Grivas, MD,...
Novel IAP Blocker Plus Chemoradiotherapy Improved Outcomes in Head and Neck Cancer Trial
Xevinapant, an investigational inhibitor of apoptosis proteins (IAP) blocker, prolonged overall survival when added to standard chemoradiotherapy for locally advanced head and neck squamous cell carcinoma, according to an updated analysis of a randomized, placebo-controlled phase II study presented ...
Expert Point of View: Fatima Cardoso, MD
The encouraging results of the phase III ASCENT trial suggest that sacituzumab govitecan has clearly earned a place in the treatment algorithm for advanced triple-negative breast cancer, said the study’s invited discussant, Fatima Cardoso, MD, Director of the Breast Unit at the Champalimaud...
Sacituzumab Govitecan Yields Survival Benefit as Third-Line Treatment in Triple-Negative Breast Cancer: ASCENT Trial
Based on results from a phase I/II clinical trial, the antibody drug conjugate sacituzumab govitecan was recently granted accelerated approval in the treatment of patients with advanced triple-negative breast cancer, contingent on a larger study confirming its benefit. The confirmatory phase III...
COVID-19, Cancer, and the Older Adult
An inspiring case series of fit patients aged 98 and older who recovered from hospitalization for COVID-19, published by Huang et al, reminds us that older age may not be a barrier to recovery.1 On behalf of the Cancer and Aging Research Group, we do not support “ageism” in the care of older...
Should Body Mass Index Guide the Choice of Chemotherapy in Patients With Breast Cancer?
The rate of obesity is rising dramatically in the United States and Europe, with more than 60% of women in the United States1,2 and 50% of women in Europe3 classified as overweight or obese based on their body mass index (BMI). Obesity is associated with an increased risk of hormone...
Expert Point of View: Christine M. Lovly, MD, PhD
Lorlatinib was strategically designed to have activity against ALK and to be highly CNS-penetrant,” said formal discussant Christine M. Lovly, MD, PhD, of Vanderbilt Ingram Cancer Center, Nashville. “We look forward to seeing more data from this trial. Alectinib had a progression-free survival of...
Lorlatinib Improves Outcomes Over Crizotinib in First-Line Setting of ALK-Positive NSCLC: CROWN Trial
Lorlatinib significantly improved progression-free survival compared with crizotinib in the first-line treatment of patients with advanced ALK-positive non–small cell lung cancer (NSCLC), according to a planned interim analysis of the phase III CROWN trial presented at the European Society for...
FDA Pipeline: Priority Reviews in EGFR-Mutant Lung Cancer, Advanced Renal Cell Carcinoma; Fast Track Designations in CLL and Solid Tumors
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to treatments for EGFR-mutant lung cancer and advanced renal cell carcinoma; granted Fast Track designation to agents in chronic lymphocytic leukemia (CLL) and locally advanced or metastatic solid tumors; and more....
Small Case Study Explores Novel Approach to Neoadjuvant Therapy for Skin Cancer
Skin cancers are the most common malignancy in the United States and worldwide. Between 1994 and 2014, the diagnosis and treatment of melanoma and nonmelanoma skin cancers in the United States increased by 77%.1 The cost of treating melanoma and nonmelanoma skin cancers to the health-care system...
Adjuvant vs Salvage Radiotherapy Plus Short-Term ADT After Radical Prostatectomy for Localized Prostate Cancer
As reported in The Lancet Oncology by Sargos et al, the French phase III GETUG-AFU 17 trial has shown no event-free survival benefit for adjuvant radiotherapy vs salvage radiotherapy—both with short-term androgen-deprivation therapy (ADT)—after radical prostatectomy in men with localized prostate...
Advanced Practitioner Leadership in Times of Crisis
In 2020, health-care providers from all disciplines are facing challenges never before encountered in the modern era of medicine. Advanced practitioners (APs) are playing critical roles in developing protocols, managing health-care teams, and delivering hands-on patient care. JADPRO Live, the...
Dr. Christina Cone Honored With The Mary Pazdur Award for Excellence in Advanced Practice in Oncology by APSHO
The Advanced Practitioner Society for Hematology and Oncology (APSHO) presented the third annual Mary Pazdur Award for Excellence in Advanced Practice in Oncology to Christina Cone, DNP, APRN, ANP-BC, AOCNP®, of Duke Cancer Institute, at the JADPRO Live Virtual conference, an annual educational...
Behavioral Nudges Combined With Machine Learning Mortality Estimates May Improve Rate of Advanced Cancer Care Conversations
An electronic nudge to clinicians—triggered by an algorithm that used machine-learning methods to flag patients with cancer who would most benefit from a conversation around end-of-life goals—tripled the rate of those discussions, according to a new prospective, randomized study of nearly 15,000...
Are Delays in Breast Cancer Treatment as Harmful as Commonly Thought?
Delays in the treatment of breast cancer matter, but not as much “as we and our patients typically assume,” Richard J. Bleicher, MD, FACS, informed participants at the 22nd Annual Lynn Sage Breast Cancer Symposium.1 Some of these delays are unavoidable and others are tradeoffs that must be made to...
Neoadjuvant Dual Checkpoint Blockade in Certain Patients With Localized Bladder Cancer
Neoadjuvant combination therapy with the anti–CTLA-4 therapy tremelimumab and the anti–PD-1 therapy durvalumab was well tolerated and showed early signs of activity in patients ineligible to receive cisplatin-based chemotherapy, all of whom had tumors with high-risk features that are associated...
Hypofractionated Stereotactic Radiotherapy to the Resection Cavity in Patients With Brain Metastases
In a multi-institutional cohort study reported in JAMA Oncology, Eitz et al found that hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity in patients with brain metastases appears to be associated with an “excellent risk-benefit profile.” As stated by the investigators, “For...
ASCO Approves First Joint MSTS/ASTRO/ASCO Guideline on Treatment of Metastatic Carcinoma and Myeloma of the Femur
On June 20, 2020, ASCO approved the first joint Musculoskeletal Tumor Society (MSTS)/American Society for Radiation Oncology (ASTRO)/ASCO guideline on the care of patients with metastatic carcinoma and myeloma of the femur.1 Guideline recommendations were based on a systematic review of clinical...
Joseph M. Unger, PhD, on Patient Interest in Clinical Trial Enrollment: A New Analysis
Joseph M. Unger, PhD, of Fred Hutchinson Cancer Research Center, discusses study results showing that more than half of all patients with cancer, regardless of race or ethnicity, agree to take part in clinical trials, a finding that upends conventional beliefs. He talks about removing the barriers...
Expert Point of View: Rodabe N. Amaria, MD
The value of adjuvant therapy for patients with resected stage III or IV melanoma—in the form of pembrolizumab and nivolumab—continues to be observed after approximately 4 years from the start of therapy, according to Rodabe N. Amaria, MD, Associate Professor of Melanoma Medical Oncology at The...
Long-Term Benefit of Adjuvant Immunotherapy Sustained in Stage III or IV Melanoma
The benefit of anti–PD-1 antibodies in the adjuvant treatment of patients with stage III or stage IV melanoma continues to be observed at around 4 years for both pembrolizumab and nivolumab, according to updates of pivotal trials presented at the European Society for Medical Oncology (ESMO) Virtual ...
Limited English-Language Proficiency May Affect Frequency of Screening Mammograms
Limited English-language proficiency may be a risk factor for receiving screening mammograms less often, according to new study results using national data. These findings, concerning women age 40 and older living in the United States, were presented at the American College of Surgeons Clinical...
Expert Point of View: Bartosz Chmielowski, MD, PhD
COMBI-i’s invited discussant, Bartosz Chmielowski, MD, PhD, Associate Clinical Professor at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, said this study is one of three key trials in which checkpoint inhibitors were combined with BRAF and MEK inhibitors. “This is...
COMBI-i Trial: No Statistical Benefit to Adding Spartalizumab to Dabrafenib/Trametinib in Melanoma
Patients with unresectable or metastatic melanoma harboring BRAF V600 mutations did not benefit from the addition of the anti–PD-1 antibody spartalizumab to dabrafenib and trametinib in the COMBI-i trial, which was presented at the European Society for Medical Oncology (ESMO) Virtual Congress...
Urine-Based Liquid Biopsy May Perform Similarly to Urine Cytology in Detecting Urothelial Carcinoma
Analysis of DNA copy number variants in the cells exfoliated in urine showed improved sensitivity and similar specificity in detecting urothelial carcinoma compared to urine cytology, according to results published by Zeng et al in Clinical Cancer Research. “Urine cytology, which is widely used to...
Long-Term Follow-up of Anti-CD19 CAR T-Cell Therapy in Relapsed B-Cell Malignancies
As reported in the Journal of Clinical Oncology by Cappell et al, long-term follow-up of a National Cancer Institute phase I trial has shown that anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for various relapsed B-cell malignancies produced responses lasting 3 years or longer in half of ...
Tazemetostat in Patients With Advanced Epithelioid Sarcoma and Loss of INI1/SMARCB1
As reported in The Lancet Oncology by Mrinal Gounder, MD, and colleagues, findings in a cohort of a phase II basket trial showed that the oral EZH2 inhibitor tazemetostat produced durable responses in some patients with advanced epithelioid sarcoma with loss of INI1 or SMARCB1 (the gene encoding...
ASCO’s Policy Statement on Skin Cancer Prevention Focuses on Four Key Areas to Reduce Incidence and Save Lives
The increasing incidence rates of skin cancer in the United States are staggering. It is the most common cancer diagnosed in the country, and current estimates show that about 9,500 Americans are diagnosed with skin cancer every day. Over the course of a year, more than 3 million people are...
Clinical Challenges of Managing Breast Cancer Brain Metastases
“Breast cancer brain metastases are a clinical challenge that are only increasing in incidence and are a consequence of advanced breast cancers, largely HER2-positive and triple-negative,” according to Carey K. Anders, MD, Professor of Medicine and Medical Director of the Duke Brain and Spine...
KEYNOTE-181 Trial: Second-Line Pembrolizumab vs Chemotherapy in Advanced Esophageal Cancer
As reported in the Journal of Clinical Oncology by Takashi Kojima, MD, and colleagues, the phase III KEYNOTE-181 trial has shown that second-line pembrolizumab improved overall survival vs investigator’s choice of chemotherapy in patients with advanced or metastatic esophageal cancer with a PD-L1...
Prognostic Model for Outcomes With Ibrutinib Treatment for Chronic Lymphocytic Leukemia
As reported in the Journal of Clinical Oncology, Ahn et al developed a four-factor model that identified risk groups for poorer outcomes among patients treated with ibrutinib for chronic lymphocytic leukemia. Study Details Patients treated with ibrutinib in phase II and III trials constituted the...
Can Routine Scans Help Predict Which Patients With Breast Cancer May Be at Risk for Heart Disease?
Automated analysis of the routine scans of patients with breast cancer may help to predict which women have a greater risk of developing cardiovascular disease, according to research presented by Gal et al at the 12th European Breast Cancer Conference (Abstract 7). Women who have been treated for...
Association of Adjuvant Chemotherapy With Survival in Early-Stage NSCLC: Do Tumor Size and High-Risk Features Have an Impact?
In a retrospective cohort study reported in JAMA Oncology, Pathak et al found that tumor size alone was not associated with improved survival with adjuvant therapy vs no adjuvant chemotherapy in patients with early-stage, node-negative non–small cell lung cancer (NSCLC). As stated by the...
